ClinicalTrials.gg
CompletedNCT05338515Updated May 18, 2025Results posted

A Study of Selpercatinib (LY3527723) in Healthy Participants

A Phase 1 interventional study of Selpercatinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Feb 2019, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to determine how safe and how well tolerated selpercatinib is when given as oral doses to healthy participants. The study will also assess how fast selpercatinib gets into the blood stream and how long it takes the body to remove it. The study will last up to about 6 weeks, inclusive of screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants of non- who are agreeable to take measures until study completion
  • (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meter squared (kg/m²) and had a minimum weight of at least 50 kg at screening
  • Have normal blood pressure, pulse rate, (ECG), and blood and urine laboratory test results that are acceptable for the study

Exclusion criteria

Exclusion Criteria:

  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Have or used to have health problems or laboratory test results or readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Had blood loss of more than 500 milliliters (mL) within the previous 30 days of study screening
  • Require treatment with inducers or inhibitors of cytochrome P450 (CYP) within 14 days before the first dose of study drug through the end of Period 2
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    320 mg Selpercatinib

    Participants received a single oral dose of 320 mg selpercatinib on Day 1, preceded by an overnight fast of at least 10 hours, followed by a fast from food (not including water) for at least 4 hours post dose.

    Drug: Selpercatinib

  • Experimental
    640 mg Selpercatinib

    Participants received a single oral dose of 640 mg selpercatinib on Day 1, preceded by an overnight fast of at least 10 hours, followed by a fast from food (not including water) for at least 4 hours post dose.

    Drug: Selpercatinib

  • Experimental
    720 mg Selpercatinib

    Participants received a single oral dose of 720 mg selpercatinib on Day 1, preceded by an overnight fast of at least 10 hours, followed by a fast from food (not including water) for at least 4 hours post dose.

    Drug: Selpercatinib

Interventions

  • Administered orally.

    Also known as: LY3527723, LOXO-292

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.

    Time frame: Baseline up to Day 8

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

    PK: AUC0-t is calculated using the linear trapezoidal with linear interpolation method.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose

  2. PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib

    PK: AUC0-24 was calculated using the linear trapezoidal with linear interpolation method.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose

  3. PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib

    PK: AUC0-inf was calculated as AUC0-inf = AUC0-t + (Clast/Kel) where Clast is the last observed/measured concentration and Kel is the apparent terminal elimination rate constant, which represents the fraction of drug eliminated per unit time.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose

  4. PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib

    PK: Percent of AUC0-inf extrapolated was calculated as (1-AUC0-t/AUC0-inf) \*100.

    Time frame: Predose -168 hours post dose

  5. PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib

    PK: CL/F was calculated as Dose/(AUC0-inf).

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose

  6. PK: Maximum Observed Concentration (Cmax) of Selpercatinib

    PK: Cmax was taken directly from bioanalytical data.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose

  7. PK: Time to Reach Cmax (Tmax) of Selpercatinib

    PK: Tmax was time to reach Cmax. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value taken from clinical database as the difference in the time of administration and the time of the blood draw which is associated with the Cmax.

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose

  8. PK: Apparent First-order Terminal Elimination Rate Constant (Kel) of Selpercatinib

    PK: Apparent terminal elimination rate constant; represents the fraction of drug eliminated per unit time calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose

  9. PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Selpercatinib

    PK: Vz/F calculated as Dose/(AUC0-inf x Kel).

    Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose

07

Results

Posted May 18, 2025

Participant flow

Participant flow — Overall Study
Milestone320 Milligram (mg) Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
Started666
Received at least one dose of study drug666
Completed666
Not completed000

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.

Time frame:
Baseline up to Day 8
Reported as:
Number · participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
participants320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration000
SecondaryPharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

PK: AUC0-t is calculated using the linear trapezoidal with linear interpolation method.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/ mL)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
nanogram*hour per milliliter (ng*h/ mL)320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib35900 ± 59.750460 ± 46.560960 ± 50.7
SecondaryPK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib

PK: AUC0-24 was calculated using the linear trapezoidal with linear interpolation method.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose
Reported as:
Geometric mean · ng*h/ mL
PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib
ng*h/ mL320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib21280 ± 79.830680 ± 50.536450 ± 58.3
SecondaryPK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib

PK: AUC0-inf was calculated as AUC0-inf = AUC0-t + (Clast/Kel) where Clast is the last observed/measured concentration and Kel is the apparent terminal elimination rate constant, which represents the fraction of drug eliminated per unit time.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/ mL)
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib
nanogram*hour per milliliter (ng*h/ mL)320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib36080 ± 59.750770 ± 46.761380 ± 50.7
SecondaryPK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib

PK: Percent of AUC0-inf extrapolated was calculated as (1-AUC0-t/AUC0-inf) \*100.

Time frame:
Predose -168 hours post dose
Reported as:
Mean · percentage
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib
percentage320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib0.5159 ± 0.446880.6238 ± 0.290080.6869 ± 0.29427
SecondaryPK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib

PK: CL/F was calculated as Dose/(AUC0-inf).

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
Reported as:
Mean · Liters per Hour (L/h)
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib
Liters per Hour (L/h)320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib10.16 ± 6.344213.62 ± 5.506012.79 ± 5.2828
SecondaryPK: Maximum Observed Concentration (Cmax) of Selpercatinib

PK: Cmax was taken directly from bioanalytical data.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Selpercatinib
nanograms per milliliter (ng/mL)320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
PK: Maximum Observed Concentration (Cmax) of Selpercatinib2282 ± 88.63316 ± 56.33745 ± 55.2
SecondaryPK: Time to Reach Cmax (Tmax) of Selpercatinib

PK: Tmax was time to reach Cmax. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value taken from clinical database as the difference in the time of administration and the time of the blood draw which is associated with the Cmax.

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
Reported as:
Median · hour
PK: Time to Reach Cmax (Tmax) of Selpercatinib
hour320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
PK: Time to Reach Cmax (Tmax) of Selpercatinib2.001 (1.50 to 3.00)1.999 (1.03 to 2.51)2.753 (2.00 to 4.00)
SecondaryPK: Apparent First-order Terminal Elimination Rate Constant (Kel) of Selpercatinib

PK: Apparent terminal elimination rate constant; represents the fraction of drug eliminated per unit time calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
Reported as:
Mean · 1/hour (1/h)
PK: Apparent First-order Terminal Elimination Rate Constant (Kel) of Selpercatinib
1/hour (1/h)320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
PK: Apparent First-order Terminal Elimination Rate Constant (Kel) of Selpercatinib0.03122 ± 0.00944080.02607 ± 0.00547910.02562 ± 0.0040999
SecondaryPK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Selpercatinib

PK: Vz/F calculated as Dose/(AUC0-inf x Kel).

Time frame:
Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
Reported as:
Mean · Liter
PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Selpercatinib
Liter320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Selpercatinib328.7 ± 156.37526.3 ± 219.99487.0 ± 158.59

Adverse events

Collected over Baseline up to Day 8. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
320 mg Selpercatinib0/6 (0%)0/6 (0%)1/6 (16.7%)
640 mg Selpercatinib0/6 (0%)0/6 (0%)1/6 (16.7%)
720 mg Selpercatinib0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 11
Most frequent other events
Event320 mg Selpercatinib640 mg Selpercatinib720 mg Selpercatinib
PalpitationsCardiac disorders0/60/61/6
DiarrhoeaGastrointestinal disorders0/61/60/6
DyspepsiaGastrointestinal disorders0/60/61/6
UlcerGeneral disorders1/60/60/6
Pain in extremityMusculoskeletal and connective tissue disorders0/60/61/6
Burning sensationNervous system disorders1/60/60/6
HeadacheNervous system disorders0/60/61/6
Dermatitis acneiformSkin and subcutaneous tissue disorders0/61/60/6
ErythemaSkin and subcutaneous tissue disorders1/60/60/6
PapuleSkin and subcutaneous tissue disorders0/61/60/6

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)320 mg Selpercatinib640 mg Selpercatinib720 mg SelpercatinibTotal
Mean37.8 ± 7.1936.7 ± 10.6939.3 ± 9.9937.9 ± 8.91
Sex: Female, Male
Sex: Female, Male(Participants)320 mg Selpercatinib640 mg Selpercatinib720 mg SelpercatinibTotal
Female1135
Male55313
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)320 mg Selpercatinib640 mg Selpercatinib720 mg SelpercatinibTotal
Hispanic or Latino33410
Not Hispanic or Latino3328
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)320 mg Selpercatinib640 mg Selpercatinib720 mg SelpercatinibTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1113
White44412
More than one race1113
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)320 mg Selpercatinib640 mg Selpercatinib720 mg SelpercatinibTotal
United States66618
08

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Mar 2019, 1 month.

Results were first posted in May 2025, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
Apr 21, 2022
StartActual
Feb 12, 2019
Primary completionActual
Mar 12, 2019
CompletionActual
Mar 26, 2019
Results first posted
May 18, 2025
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05338515
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Apr 21, 2022
Start date
Feb 12, 2019
Primary completion
Mar 12, 2019
Completion
Mar 26, 2019
Results posted
May 18, 2025
Last update
May 18, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion